California State Teachers Retirement System Sells 53,130 Shares of Medtronic PLC $MDT

California State Teachers Retirement System lowered its holdings in Medtronic PLC (NYSE:MDT) by 2.5% in the first quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 2,038,830 shares of the medical technology company’s stock after selling 53,130 shares during the period. California State Teachers Retirement System’s holdings in Medtronic were worth $176,665,000 as of its most recent filing with the Securities and Exchange Commission.

Other hedge funds and other institutional investors have also recently added to or reduced their stakes in the company. Empowered Funds LLC boosted its holdings in shares of Medtronic by 8.5% in the 1st quarter. Empowered Funds LLC now owns 198,488 shares of the medical technology company’s stock valued at $17,199,000 after buying an additional 15,563 shares during the last quarter. The Manufacturers Life Insurance Company increased its holdings in Medtronic by 1.2% during the first quarter. The Manufacturers Life Insurance Company now owns 5,413,353 shares of the medical technology company’s stock worth $469,065,000 after buying an additional 63,296 shares during the last quarter. KCM Investment Advisors LLC raised its position in Medtronic by 3.5% during the first quarter. KCM Investment Advisors LLC now owns 14,579 shares of the medical technology company’s stock worth $1,263,000 after acquiring an additional 488 shares in the last quarter. Glen Eagle Advisors LLC lifted its stake in Medtronic by 5.5% in the first quarter. Glen Eagle Advisors LLC now owns 8,272 shares of the medical technology company’s stock valued at $717,000 after acquiring an additional 432 shares during the last quarter. Finally, Gateway Wealth Partners LLC acquired a new position in shares of Medtronic during the 1st quarter worth about $536,000. 82.06% of the stock is currently owned by institutional investors and hedge funds.

Medtronic Stock Up 3.1%

MDT stock opened at $86.87 on Wednesday. Medtronic PLC has a fifty-two week low of $73.31 and a fifty-two week high of $106.33. The company has a debt-to-equity ratio of 0.52, a current ratio of 2.13 and a quick ratio of 1.62. The stock has a market capitalization of $111.20 billion, a price-to-earnings ratio of 23.29, a PEG ratio of 2.26 and a beta of 0.56. The business’s fifty day moving average price is $80.46 and its two-hundred day moving average price is $87.25.

Medtronic (NYSE:MDT) last announced its earnings results on Wednesday, June 3rd. The medical technology company reported $1.55 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.54 by $0.01. Medtronic had a net margin of 13.20% and a return on equity of 14.51%. The company had revenue of $9.81 billion during the quarter, compared to analysts’ expectations of $9.62 billion. During the same quarter in the previous year, the business posted $1.62 earnings per share. Medtronic’s quarterly revenue was up 9.9% on a year-over-year basis. Medtronic has set its FY 2027 guidance at 5.900-6.000 EPS. On average, equities analysts anticipate that Medtronic PLC will post 5.94 earnings per share for the current year.

Medtronic Increases Dividend

The firm also recently disclosed a quarterly dividend, which was paid on Friday, July 17th. Shareholders of record on Friday, June 26th were issued a $0.72 dividend. The ex-dividend date of this dividend was Friday, June 26th. This represents a $2.88 dividend on an annualized basis and a yield of 3.3%. This is an increase from Medtronic’s previous quarterly dividend of $0.71. Medtronic’s payout ratio is presently 77.21%.

Wall Street Analysts Forecast Growth

Several brokerages recently issued reports on MDT. Rothschild & Co Redburn cut their target price on shares of Medtronic from $111.00 to $106.00 and set a “buy” rating for the company in a research note on Friday, June 5th. Wells Fargo & Company cut their price objective on Medtronic from $114.00 to $102.00 and set an “overweight” rating for the company in a research report on Thursday, June 4th. Robert W. Baird reduced their target price on Medtronic from $93.00 to $85.00 and set a “neutral” rating for the company in a research note on Thursday, June 4th. Jefferies Financial Group reissued a “hold” rating and set a $88.00 target price on shares of Medtronic in a report on Thursday, June 4th. Finally, Piper Sandler reaffirmed a “neutral” rating and set a $85.00 price target on shares of Medtronic in a report on Tuesday, June 16th. Eighteen equities research analysts have rated the stock with a Buy rating and nine have issued a Hold rating to the stock. Based on data from MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus target price of $98.83.

Medtronic News Roundup

Here are the key news stories impacting Medtronic this week:

• Positive Sentiment: Medtronic completed its $650 million acquisition of SPR Therapeutics and launched the ViaVerte system at ASPN 2026. The deal expands the company’s non-opioid pain-management portfolio and could provide a new avenue for growth in pain therapy. Medtronic Completes $650 Million SPR Deal And Launches ViaVerte
• Positive Sentiment: Brokerages have assigned Medtronic an average “Moderate Buy” recommendation, indicating that analysts generally see upside or support at current valuation levels. Medtronic Given Average Recommendation of Moderate Buy
• Neutral Sentiment: Valuation analysis suggests MDT is near fair value on a discounted-cash-flow basis but may screen as undervalued on earnings multiples. Shares are near a five-year low after an approximately 25% five-year decline, which may attract value investors, though the analysis notes execution and growth risks. Medtronic Stock May Be Fairly Valued As Shares Sit Near A 5 Year Low
• Neutral Sentiment: MDT recently outperformed the broader market in a session that ended at $84.22, reflecting improving short-term momentum but offering no major fundamental catalyst by itself. Medtronic Outpaces Stock Market Gains
• Negative Sentiment: Medtronic initiated a voluntary Class II recall of its DLP One-Piece Pediatric Arterial Cannula after two complaints involving loose foreign material with trace blood levels. The recall may raise product-quality, regulatory and reputational concerns, although its impact on company-wide results is not yet clear. Is Medtronic Fairly Valued After Its Pediatric Cannula Recall?

Insider Transactions at Medtronic

In other Medtronic news, EVP Harry Skip Kiil sold 4,189 shares of the stock in a transaction that occurred on Monday, June 8th. The shares were sold at an average price of $80.44, for a total transaction of $336,963.16. Following the transaction, the executive vice president owned 37,227 shares in the company, valued at $2,994,539.88. This represents a 10.11% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. 0.26% of the stock is owned by corporate insiders.

Medtronic Profile

Medtronic plc is a global medical technology company that develops and manufactures a broad range of therapeutic devices and health care solutions. Headquartered legally in Ireland with principal operational offices in the United States, the company markets products to hospitals, physicians and health systems worldwide and has grown from its founding in 1949 into one of the largest medical-device manufacturers serving global health-care markets.

Medtronic’s offerings span several clinical areas, including cardiac rhythm and heart failure (pacemakers, implantable cardioverter‑defibrillators and related cardiac therapies), minimally invasive and surgical technologies (laparoscopic and advanced energy devices, visualization systems and surgical innovations), restorative therapies (spine and orthopedics, neuromodulation and neurovascular treatments) and diabetes management (insulin-delivery systems and glucose monitoring solutions).